Price
$586.67+5.03%Social Signal Score
Analyst Ratings
23 analystsRevenue
$1.22B+171.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Erickson
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 11,000
- Beta
- 1.54
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 19.06
Financials
Revenue
$1.22B+171.4%Net Income
$338.41M+499.4%EBITDA
$468.46M+329.5%Free Cash Flow
$322.52M+265.6%EPS (diluted)
$4.19+575.8%Shares Outstanding (diluted)
80.67M-11.5%Operating Expenses
$353.52MCash & Debt
$196.93MReturn of Capital
$346.80MRevenue by Segment (annual)
$4.30BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.30B | $1.06B | $13.17 |
| 2024 | $3.90B | $887.87M | $10.77 |
| 2023 | $3.66B | $845.04M | $10.17 |
| 2022 | $3.37B | $679.09M | $8.12 |
| 2021 | $3.22B | $744.85M | $8.74 |
| 2020 | $2.71B | $581.78M | $6.82 |
| 2019 | $2.41B | $427.72M | $4.97 |
| 2018 | $2.21B | $377.03M | $4.34 |
| 2017 | $1.97B | $263.14M | $3.00 |
| 2016 | $1.78B | $222.04M | $2.47 |
| 2015 | $1.60B | $192.08M | $2.07 |
| 2014 | $1.49B | $181.91M | $1.82 |
| 2013 | $1.38B | $187.80M | $1.77 |
| 2012 | $1.29B | $178.27M | $1.62 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IDXX's reported EPS growth of 17.5% a year over 13 years.
- EPS in 5 years
- $29.63
- Implied price
- $1,511
- Return from $518.39
- 23.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $751.18 — today's price is already 31.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| 7.5% | 5.1% | 9.5% | 13.3% | 16.7% | 19.7% |
| 12.5% | 10.0% | 14.6% | 18.6% | 22.1% | 25.2% |
| 17.5% | 14.9% | 19.7% | 23.9% | 27.5% | 30.8% |
| 22.5% | 19.8% | 24.8% | 29.1% | 32.9% | 36.4% |
| 27.5% | 24.6% | 29.9% | 34.4% | 38.4% | 41.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
101+51.87%Social Signal Score
Mentions (24)
- 4chan /biz/biz·3d ago·Neutral
btw if you don't like IDXX replace it with FICO
View source ↗ - 4chan /biz/biz·3d ago·Neutral
…pite that, you can't even imagine all the research that I've done. Here you go. 10 ticker portfolio: >BRK.B 12.5% >JNJ 7.5% >AVGO 15% >CDNS 12.5 >IDCC 12.5 >MA 10% >IDXX 10% >VRSK 7.5% >BMI 7.5% >USLM 5% If you want a more aggressive 6 ticker portfolio. Higher risk for potentially higher reward: >BRK.B 20% >AVGO 25% >IDCC 15% >IDXX 15% >MA 12.5% >BMI 12.5%
View source ↗ - Newsbusinesswire.com·4d ago·Neutral
IDEXX Laboratories to Release 2026 Third Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, a…
View source ↗ - Newszacks.com·12d ago·Neutral
Should You Continue to Hold IDXX Stock in Your Portfolio? IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
View source ↗ - Newsmarketbeat.com·15d ago·Positive
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
View source ↗ - News (RSS)yahoo·16d ago·Negative
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics
View source ↗ - Newszacks.com·18d ago·Positive
IDEXX Stock Gains Following the Acquisition of CoVet IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
View source ↗ - Newsbusinesswire.com·19d ago·Neutral
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
View source ↗ - News (RSS)investing·19d ago·Neutral
IDEXX acquires AI veterinary workflow software firm CoVet
View source ↗ - News (Marketaux)gurufocus.com·21d ago·Positive
IDEXX Laboratories, Inc. at Morgan Stanley Global Healthcare Conference Transcript We're happy to have IDEXX L[+302 characters]
View source ↗ - Newsseekingalpha.com·21d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·25d ago·Negative
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.
View source ↗ - Newszacks.com·35d ago·Positive
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·42d ago·Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·45d ago·Neutral
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now? IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
View source ↗ - Newszacks.com·46d ago·Neutral
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
View source ↗ - Newszacks.com·47d ago·Positive
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation? IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
View source ↗ - News (RSS)seekingalpha·48d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
View source ↗ - Newsseekingalpha.com·48d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
View source ↗ - News (RSS)seekingalpha·48d ago·Neutral
IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution
View source ↗ - News (RSS)seekingalpha·52d ago·Neutral
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
View source ↗ - Newszacks.com·54d ago·Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
IDEXX Laboratories: Worth The Premium IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $3.71 per share
Typical surprise +8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$4.27 vs $3.94beat
- Tue, May 5$3.47 vs $3.41beat
- Mon, Feb 2$3.08 vs $2.93beat
- Mon, Nov 3$3.40 vs $3.14beat
- Mon, Aug 4$3.63 vs $3.28beat
- Thu, May 1$2.96 vs $2.85beat
Estimates and results for IDXX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IDXX officers and directors.
- Bought
- —
- Sold
- $23.7m
0 trades
24 trades
- Kingsley Lawrence Dsold
- Hunt Nimratasold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Feb 3, 2026 (21d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jan 6, 2026 (35d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (20d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (7d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Oct 8, 2025 (34d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Oct 8, 2025 (34d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 3, 2025 (27d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 3, 2025 (33d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 6, 2025 (28d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$100,001 - $250,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Buy$50,001 - $100,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (25d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (31d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (23d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (28d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.